AT-527

A leader in the discovery of oral direct-acting antiviral therapies.

Atea’s most advanced antiviral drug candidate, AT-527, is being evaluated in a multi-national multi-center Phase 2 clinical trial for the treatment of patients with moderate COVID-19 and risk factors for poor outcomes. As an orally-administered direct-acting antiviral, AT-527 is designed to arrest the progression of COVID-19 by inhibiting replication of the SARS CoV-2 virus.

Learn More

ATEA PHARMACEUTICALS

Innovative discovery and efficient development of potentially transformative therapies for patients with life-threatening viral diseases.

Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.

OUR SCIENCE

The power of our purine nucleotide prodrug platform.

Leveraging our platform, we have discovered and are rapidly advancing novel oral direct-acting antiviral drug candidates. Utilizing unique chemical modifications, these product candidates are designed to have the potential for enhanced antiviral activity and selectivity.

A network of hubs and spokes is suspended, representing the idea of a modular platform.

COVID-19

What we're up against.

COVID-19 is a global public health and economic crisis that continues to impact populations at an unprecedented rate. Medical and scientific communities are avidly investigating the clinical manifestations of COVID-19 and the deceptive dimensions of subclinical infection with SARS-CoV-2, the virus responsible for COVID-19.

As a result, our knowledge about the disease and the virus is evolving. Stay up-to-date on the latest facts and findings from reputable sources.

GLOBAL

Public Health Emergency

HIGH

Transmission Rate

NO

No Available Vaccine

NO

No Oral Therapeutic

NEWS

Follow our progress.

See updates on AT-527, other Atea product candidates and company news.

Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

BOSTON, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections,

Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan

Experienced Financial Executive Brings Leadership and Public Company Expertise BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to

Atea Pharmaceuticals Announces Closing of Initial Public Offering

Full Exercise of the Underwriters’ Overallotment Brings Additional $45 Million BOSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to